Evidence map›Paper›PMID 41221046›Full record

ArticleFrontiers in pharmacology2025

Proanthocyanidins from

Carla Sens-Albert, Markus Schmitt, Gabriele Luderer, Beatrix C König, Silas F Melcher, Heike Schneider, Simone Kaiser, Sabine Tremmel, Sabrina Weisenburger, Žarko Kulić and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Carla Sens-Albert *Preclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Markus Schmitt *Preclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Gabriele LudererPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Beatrix C KönigPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Silas F MelcherPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Heike SchneiderPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Simone KaiserPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Sabine TremmelPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Sabrina WeisenburgerPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Žarko KulićPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Martin D LehnerPreclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Extracts from Methods: In the present study, we used Results: Ginkgo PACs concentration dependently reduced the basal cellular production of reactive oxygen species (ROS) in the rat neuronal cell line RN46A with higher potency than the ginkgo extract EGb 761 Conclusion: A PAC fraction isolated from EGb 761

Indexed as

cognitive impairmentGinkgo biloba leaf extractherbal medicinal productsproanthocyanidinsscopolamine

Identifiers

PMID41221046
PMCPMC12597941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.